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3Who is this  
toolkit for?
The increasing use of NPS within secure environments is presenting prison-based 
staff with a significant set of new challenges. This toolkit supports custodial, 
healthcare and substance misuse staff by providing information about the extent 
of NPS use as we currently understand it and about the properties of the various 
categories of NPS, and by providing advice on how to manage the problem from a 
clinical, psychosocial and regime perspective.    
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5■ NPS, also known as legal highs or research 
chemicals, continue to present a challenge to 
treatment services in the community and in 
prisons
■ problematic terminology: often not new,  
legal or ‘high’ inducing
■ significant variations across the country;  
regional/local subcultures and micro-cultures
■ people may use them for experimental, 
recreational purposes or if they have  
become dependent on them
■ shifting patterns of use due to variable purity 
and cost, along with perceptions of legal status 
and their desired or adverse effects
What do we mean by NPS?
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7■ January 2015 – MoJ applies a range of 
measures to address NPS use in prisons
 www.gov.uk/government/news/new-crackdown-on- 
dangerous-legal-highs-in-prison
■ Serious Crime Act 2015 the new legislation 
makes it a crime to throw any object into  
a prison, including NPS 
 www.legislation.gov.uk/ukpga/2015/9/pdfs/ukpga_ 
20150009_en.pdf
■ Psychoactive Substances Bill 2015.  
Queen’s speech “new legislation will… ban  
the new generation of psychoactive drugs” 
 www.gov.uk/government/collections/psychoactive- 
substances-bill-2015
■ local authorities, supported by the police, will 
continue to use a variety of trading standards 
and consumer legislation, along with measures 
to prevent antisocial behaviour and to protect 
public spaces, in order to address the problem 
in community settings
The law
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9■ project NEPTUNE (March 2015) has been developed to improve  
clinical practice in managing harm resulting from club drugs and 
NPS use. It divides these drugs into four categories: 
Categories of NPS
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1. Synthetic  
cannabinoids (SC) 
include a large number of 
drugs, the best known and 
most widely used being 
Spice and Black Mamba
2. Depressants  
include such drugs 
as GHB (gamma 
hydroxybutyrate), GBL 
(gamma butyrolactone) 
and ketamine, which has 
dissociative effects in 
addition to its depressant 
effects
3. Stimulants 
include drugs like MDMA 
(3,4-methylene-dioxxyme-
thamphetamine), better 
known as ecstasy, and 
ecstasy variants such as 
PMA (paramethoxyam-
phetamine) and PMMA 
(paramethoxymethamphet-
amine)
4. Hallucinogens 
include drugs such as LSD 
(lysergic acid diethylamide) 
and assorted tryptamines 
and phenethylamines
www.neptune-clinical-guidance.co.uk 
The current evidence indicates that the majority of NPS 
circulating in the prison system are synthetic cannabinoids
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■ prison staff consistently express  
concern about high rates of SC use (usually 
Spice and Black Mamba), including by 
prisoners without a prior history of drug 
misuse
■ Nick Hardwick, HM Chief Inspector of Prisons, 
stated in September 2015 that two-thirds  
of prisons reported having a “significant 
issue” with NPS in 2014-15 compared  
to one-third in 2013-14
■ healthcare staff report a significant  
impact on their day-to-day workload  
as a consequence of dealing with the  
acute adverse effects of Spice
Prevalence: anecdotal reports
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A recent response to a parliamentary question (209374) reported  
that seizures of Spice have increased from 15 in 2010 to 430 during the seven 
months from 1 January to 31 July 2014. During the same period, there were only 
21 seizures of ketamine, mephedrone and benzylpiperazine combined 
(see table below, www.gov.uk/government/news/new-crackdown-on-dangerous-legal-highs-in-prison)
Prevalence: seizures
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1 Jan 2010 to  
31 Dec 2010
1 Jan 2011 to 
31 Dec 2011
1 Jan 2012 to 
31 Dec 2012
1 Jan 2013 to 
31 Dec 2013
1 Jan 2014 to 
31 July 2014
Mephedrone 0 0 0 3 2
BZP 0 1 0 0 0
Spice 15 86 133 262 430
Ketamine 1 3 5 2 4
Total 16 90 138 267 436
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Conversely, positive tests for traditional  
cannabis fell by 59% (from 8.6% to 3.9%  
positive results) between 2003-04 and 2013-14 
Centre for Social Justice 2015: 
www.centreforsocialjustice.org.uk/UserStorage/pdf/Pdf%20
reports/CSJJ3090_Drugs_in_Prison.pdf
As a result of increasing concerns around  
the availability and use of NPS in prisons, the  
Home Office Forensic Early Warning System 
(FEWS) has undertaken an analysis of seized 
inbound samples to identify the types of NPS 
being smuggled into prisons. Of the 893 samples 
analysed, 762 were found to be NPS. See table 
overpage 
Prevalence: seizures (continued)
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Samples of drugs seized being  
brought in to prison
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www.gov.uk/government/uploads/system/uploads/attachment_data/file/461333/1280_EL_FEWS_Annual_Report_2015_WEB.pdf
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■ undetectable by conventional onsite  
testing, make time pass more quickly  
and easier to get hold of
■ relative affordability, but emerging  
evidence that this may be changing
■ the unpredictable effects of SC may be an 
attractive feature of these drugs to some 
prisoners who wish to experiment or be  
more adventurous with their drug use
■ prior to the Ministry of Justice applying 
sanctions for NPS possession and use in 
January 2015, uncertainty in relation to  
their legal status may have contributed  
to the popularity of NPS among prisoners
Reasons for the popularity 
of NPS, particularly SC 
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■ as with all illicit drug use in prison, the covert 
nature of NPS use, the unpredictable effects 
of the drugs and the delay in seeking medical 
help all combine to have a significant impact 
on healthcare staff
■ the adverse effects of NPS in general are 
discussed in more detail at the end of the 
toolkit but, in view of the prevailing concerns 
about SC, we briefly consider some of their 
adverse effects in this part of the document
■ some of the extreme effects of SC 
(convulsions, bizarre behaviour, temporary 
paralysis, rapid heart rate, aggression and 
psychosis) require an immediate response and 
may require transfer to hospital
■ the adverse effects of SC use can be long 
lasting, and custody and healthcare staff  
may have to manage the consequences for 
months following the initial presentation
■ some prisoners who use SC may not see 
themselves as having a problem with their use, 
so may be reluctant to engage with substance 
misuse teams or take measures to reduce or 
discontinue their use of the drugs, but they 
should be given every encouragement and 
support to do so
Challenges for healthcare staff 
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■ the rapidly increasing prevalence of NPS in 
prisons is placing additional demands on prison 
and security staff resources in terms of supply 
disruption, searching and detection activities
■ the need to restrain and control prisoners 
behaving abnormally or dangerously, or 
to transfer prisoners to hospital, or to 
manage long-term challenging or aggressive 
behaviour, clearly have implications for 
custodial staff within prisons
■ Nick Hardwick, HM Chief Inspector of Prisons, 
stated in September 2015 that increased 
use of NPS in prisons would appear to be 
contributing to rising problems with debt, 
bullying and violence, and that evidence 
suggests organised crime groups are 
supplying NPS to prisons
Challenges for the 
wider prison regime
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■ establishing accurate data on the prevalence, 
use and effects of NPS remains crucial to 
determining successful management of the 
problems associated with these drugs
■  it is essential that every establishment has an 
integrated response, with custodial, health 
and psychosocial care staff taking a joint 
approach to managing all aspects of the 
problems associated with SC in prisons
■  this integrated response is underpinned  
by a multimedia campaign directed at 
prisoners and visitors, describing the 
consequences and sanctions for  
possessing and using NPS
■  the overriding principle is that staff  
should respond in a proportionate and 
relevant way to presenting behaviour  
or symptoms, irrespective of whether 
prisoners are suspected to be under the 
influence of NPS
 Prison healthcare providers should follow existing  
PHE guidance that the appropriate response  
is to address symptoms rather than the specific drug
 Where there are questions about prisoners’  
mental capacity when under the influence of  
NPS, staff should apply the principles set out in  
the NHS choices consent to treatment guidance
 (www.nhs.uk/Conditions/Consent-to-treatment/Pages/
Capacity.aspx)
 Issues related to control and restraint are covered  
by PSO 1600 – Use of force
Management of NPS in prisons
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■ in general, no specific pharmacological 
treatments exist for the adverse effects 
of NPS, so symptom-directed supportive 
care will inform the safe and effective 
management of acute presentations, 
underpinned by advice from the National 
Poisons Information Service and its online 
toxicology database and telephone enquiry 
service TOXBASE
■  the mainstay of longer-term treatment will 
be the appropriate clinical and psychosocial 
support as described in the Project NEPTUNE 
guidance document. So substance misuse 
services may need to adapt their current 
treatment practices in order to better address 
the needs of people using NPS
 (www.neptune-clinical-guidance.co.uk/wp-content/
uploads/2015/03/NEPTUNE-Guidance-March-2015.pdf)
Management of NPS in prisons 
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Desired effects
Relaxation, euphoria, disinhibition,  
feeling energised, altered consciousness 
 
 
 
Adverse effects
Acute: convulsions, paralysis, psychosis, 
extreme bizarre behaviour, tachycardia, 
aggression
Without rapid urine or blood tests to 
confirm the use of SC (or other drugs), 
assesment has to be clinical, based on 
history where available, and recognising 
the clinical presentation
Chronic: psychosis, aggression 
Users/modes of use
Users: prisoners, workers subject to  
drug testing, students, graduates 
Modes of use: smoked in joints or inhaled 
through a bong, rarely ingested or snorted 
Treatment
Acute: symptom-directed supportive care, 
may require medication for agitation, 
convulsions, or psychosis
If symptoms are persistent or severe 
transfer to hospital may be necessary 
Chronic: psychosocial and other 
appropriate support. Pharmacotherapy, 
where appropriate, for enduring symptoms 
 
Synthetic  
cannabinoids
Class B where 
classified
More  
information  
online
Note that while the evidence indicates SC account for the 
majority of NPS currently used in prisons, we recognise 
that the situation is fluid and subject to change and so have 
included information on the four categories of NPS and club 
drugs described in Project Neptune
Street names
Annihilation  
Amsterdam Gold
Spice
Black Mamba
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Desired effects
Euphoria, relaxation, increased sociability, 
increased libido, sexual disinhibition  
 
Adverse effects
Acute: overdose – tolerance does not 
necessarily confer protection and the risk 
of coma or death will be increased if taken 
with other depressant drugs such as alcohol 
or benzodiazepines. Other acute effects 
include drowsiness, cardiac, respiratory and 
gastrointestinal symptoms, hypothermia
Chronic: severe dependence 
Users/modes of use
Users: clubbers, especially popular with 
MSM (men who have sex with men), 
chemsex scene 
Modes of use: usually orally, mixed with 
a drink due to its salty taste, occasionally 
snorted, rarely injected 
 
Treatment
Acute: symptom-directed supportive care, 
especially respiratory support and airway 
protection. Symptoms are usually short-lived, 
but if severe or persistent, transfer to hospital 
may be necessary 
Chronic: motivational interviewing, 
relapse prevention, psychosocial support.
Benzodiazepines and baclofen may be 
used to treat withdrawal symptoms. Acute 
withdrawal symptoms may be a medical 
emergency, requiring treatment with 
barbiturates 
 
Depressants
Gamma
Hydroxybutyrate 
(GBH) Class C
Gamma
Butyrolactone 
(GBL) Class C
More  
information  
online
Street names
Gina Gamma-O 
Blue Verve 
Liquid E 
Liquid Ecstasy 
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Desired effects
Dissociation, intense detachment (k-hole),  
perceptual disorders, auditory and visual 
hallucinations 
 
Adverse effects
Acute: nausea, slurred speech, dizziness, 
collapse, accidential injury, agitation, 
tachycardia, visual hallucinations
In the absence of rapid urine or blood tests 
to confirm the use of ketamine (or other 
drugs), assesment has to be clinical, based 
on history, where available, and recognising 
the clinical presentation
Chronic: ulcerative cystitis, k-cramps,  
psychosis, dependence  
Users/modes of use
Users: young (20-24), single, unemployed,  
students clubbers, MSM (men who have 
sex with men), polydrug users
Modes of use: snorted, rarely orally  
or injected 
 
Treatment
Acute: symptom-directed supportive care 
until symptoms, which are usually short 
lived, resolve
Chronic: motivational interviewing, relapse 
prevention, psychosocial support, bladder 
monitoring, pain management, psychosocial 
support 
 
Depressants/dissociative
Ketamine  
Class B
More  
information  
online
Street names
Ket  
Special K 
Kit-Kat, Super K  
Cornflakes
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Desired effects
“The ego of cocaine and loved-up feeling 
of ecstasy”, euphoria, elevated mood, 
reduced hostility, increased sensuality, 
improved sexual functioning, prolonged 
sexual performance 
 
Adverse effects
Acute: psychosis, jaw clenching, teeth 
grinding, tremor, tachycardia, headache, 
convulsions
In the absence of rapid urine or blood 
tests to confirm the use of mephedrone (or 
other drugs), assesment has to be clinical, 
based on history, where available, and 
recognising the clinical presentation
Chronic: psychosis, depression, anxiety, 
congnitive impairment, dependence 
Users/modes of use
Users: clubbers (especially gay clubbers), 
polydrug users adding to existing drug 
repertoire – rationale for polydrug use may 
be quite sophisticated 
Modes of use: snorted, can irritate nose 
and cause nosebleeds. Swallowed (usually 
in a drink or bombed due to its bad taste), 
injected 
 
Treatment
Acute: symptom-directed supportive 
care, managing agitation, convulsions, 
hypotension, hypertension and 
rhabdomyolysis in particular
If symptoms are severse or persistent, 
transfer to hospital may be necessary 
Chronic: motivational Interviewing, relapse 
prevention, psychosocial support, treat any 
co-morbid conditions, anti-psychotics 
 
Stimulants 
Mephedrone  
Class B
More  
information  
online
Street names
Bubbles(s)
Miaow 
Meow-Meow 
Mcat
 Top Cat 
Mad-dog Roxy 
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Desired effects
Energy, euphoria, empathy, “loved up” 
 
Adverse effects
Acute: hyperthermia, hyponatraemia (women 
especially), tachycardia, hypertension, 
serotonin syndrome, collapse, convulsions, 
hallucinations, headache, sweating, kidney 
injury, delayed orgasm, erectile dysfunction 
In the absence of rapid urine or blood tests to 
confirm the use of ecstacy (or other drugs), 
assesment has to be clinical, based on 
history, where available, and recognising the 
clinical presentation
Chronic: cognitive impairment, neurotoxicity, 
depression, increased suicide risk 
Users/modes of use
Users: clubbers, young people, students, 
polydrug users, 95% of time taken with 
alcohol 
Modes of use: bombing crystals or powder 
is most common; also swallowed in tablet 
form and, rarely, dabbed 
 
Treatment
Acute: symptom-directed supportive 
care while awaiting transfer to hospital 
for more specific treatment, such as 
cooling, management of dehydration and 
hyponatraemia
Chronic: psychosocial support, 
symptomatic support
Avoid monoamine oxidase inhibitors and 
selective serotonin reuptake inhibitors 
 
Stimulants
Ecstasy  
(MDMA) Class A
Variants  
(PMA/PMMA)  
Class A
More  
information  
online
Street names
E, Molly
Mandy
MD
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Desired effects
Euphoria, mild stimulation, altered sense 
of time and space, enhanced appreciation 
of music, visual distortions, intensified 
sensual or sexual feelings 
 
Adverse effects
Acute: dysphoria, panic, paranoia, tremor, 
tachycardia, tremor, hyperthermia, 
depersonalisation
In the absence of rapid urine or blood tests 
to confirm the use of hallucinogens (or 
other drugs), assesment has to be clinical, 
based on history, where available, and 
recognising the clinical presentation
Chronic: dependence (rare), flashbacks, 
persisting perceptual disorder 
Users/modes of use
Users: young (16-24), polydrug users, used 
relatively infrequently 
Modes of use: orally, sublingually, buccal, 
rarely snorted  
Treatment
Acute: symptom-directed supportive care 
until symptoms (usually mild and transient) 
have resolved
Chronic: supportive-dependence is rare  
 
Hallucinogens 
Lysergamides
(Class A) 
Tryptamines
(Class A) 
Phenethylamines
(Class A) 
More  
information  
online
Street names
LSD, Acid, A tab, Blotter, 
Geltabs, Windowpane 
Street names
Magic mushrooms,  
Mushies, Shrooms
Street names
Mescaline-Peyote, San 
Pedro, Peruvian Torch, Bees, 
Nexus, N-Bomb
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